Filtered By:
Drug: Herceptin
Management: Health Insurance
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis
CONCLUSION: Trastuzumab in real-world practice was associated with an increased risk of HF, but was not associated with an increased risk of Af in BC patients. Trastuzumab-induced arrhythmogenic effects may be masked by concurrent heart-protecting measures, more prominent roles of comorbidities or concurrent medications under real-world settings. Further studies are required.PMID:36586037 | DOI:10.1007/s10549-022-06753-7
Source: Cell Research - December 31, 2022 Category: Cytology Authors: Wen-Chi Wu Chi-Cheng Huang Yi-Fang Tsai Yen-Shu Lin Chin-Jung Feng Yen-Jen Chen Jiun-I Lai Ta-Chung Chao Chun-Yu Liu Ling-Ming Tseng Source Type: research
Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
CONCLUSIONS AND RELEVANCE: In this longitudinal cohort study, premenopausal Korean women with breast cancer who received tamoxifen as adjuvant hormone therapy had a significantly increased risk of endometrial hyperplasia, polyps, carcinoma, and other uterine cancers compared with those who were not treated with adjuvant hormone therapy. These findings suggest that clinicians should consider the risk of uterine disease among tamoxifen users, including premenopausal women.PMID:36441547 | DOI:10.1001/jamanetworkopen.2022.43951
Source: Cancer Control - November 28, 2022 Category: Cancer & Oncology Authors: Ki-Jin Ryu Min Sun Kim Ji Yoon Lee Seunghyun Nam Hye Gyeong Jeong Tak Kim Hyuntae Park Source Type: research
Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
CONCLUSION: The trastuzumab biosimilar combination regimen is cost-effective and offers significant drug cost savings in Taiwan.PMID:35870421 | PMC:PMC9305615 | DOI:10.1016/j.breast.2022.07.007
Source: Breast - July 23, 2022 Category: Cancer & Oncology Authors: John Hang Leung Yun-Sheng Tai Shyh-Yau Wang Hei-Tung Yip Fion Ho Tsung-Chin Agnes Lf Chan Source Type: research
Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group
CONCLUSION: The risk of death was low in women who became pregnant ≥49 months after the diagnosis of breast cancer. The prognosis of pregnant women was non-inferior to that of non-pregnant women, even in women who received trastuzumab. These findings provide reassurance to patients with HER2-positive cancer who are considering future pregnancy.PMID:35299034 | PMC:PMC8927839 | DOI:10.1016/j.breast.2022.03.005
Source: Breast - March 17, 2022 Category: Cancer & Oncology Authors: Soo Youn Bae Jihyoun Lee Ji Sung Lee Jae Sun Yoon Ku Sang Kim Yoo Seok Kim Zisun Kim Jun Won Min Eun-Jung Shim Ilkyun Lee Min Hyuk Lee Sungmin Park Source Type: research
